CEO/Co-Founder
C
Contraline
Contraline is developing ADAM™, a long-lasting, non-hormonal implant for male contraception that functions similarly to an IUD. This device addresses the need for a reliable and reversible contraceptive option for men, eliminating the anxiety and inconvenience associated with current methods.
- Biotechnology
Updated yesterday
Funding
Raised to date
$35.9MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+2Funding rounds are not available yet.
Founders
Product
Problem
Current male contraceptive options are limited to condoms or vasectomy, with a lack of long-lasting, reversible, and hormone-free alternatives. This gap leaves many men without convenient or appealing choices for family planning.
Solution
Contraline is developing ADAM™, a long-lasting, non-hormonal male contraceptive implant designed to function similarly to an IUD. The device is placed in the vas deferens to block sperm flow, providing a reversible method of contraception. ADAM™ aims to offer men a reliable and convenient option that eliminates the anxiety and inconvenience associated with existing methods, without the use of hormones. Clinical trials for ADAM™ have begun, marking a significant step toward expanding male contraceptive choices.
Target Audience
The primary target audience is men seeking a long-lasting, reversible, and non-hormonal alternative to condoms or vasectomy for contraception.
Features
- Non-hormonal mechanism of action, avoiding hormonal side effects
- Long-lasting contraceptive effect, reducing the need for frequent action
- Reversible design, allowing men to restore fertility if desired
- Implantable device placed in the vas deferens
- Designed to block sperm flow